Study on Global Peptide Based Infection Therapeutics Market Highlights Key Development Factors and Upcoming Trends forecast Till 2022

Rockville, US, 2018-Dec-10 — /EPR Network/ — There is a need to develop novel therapeutic agents in order to fight infections. Peptide therapeutics are used to fight infectious diseases. The global peptide based infection therapeutics market is expected to grow in the future owing to factors such as cost effectiveness of peptides, higher efficacy of peptides in managing various disease indications and infections, and can be easily synthesized owing to smaller size. Moreover, few economic factors such as government policies for startup companies, increasing foreign direct investment, as well as higher investment in healthcare are also driving the global peptide based infection therapeutics market. The rising prevalence of infectious diseases has resulted in providing an impetus to the use of peptides therapeutics to treat infections. Along with this, emerging biotech and pharmaceutical companies, strong and advanced pipelines and patent expiries are few other aspects impacting the growth of the global peptide based infection therapeutics market positively. To support this, the advancements in technology and increased research and development and the rising investments in these fields have led to the growing importance of global peptide based infection therapeutics market. North America is expected to show higher attractiveness in this market.

Get Free Sample Report here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=188

6 Forecast Highlights on Global Peptide Based Infection Therapeutics Market

1. North America expected to show higher market attractiveness and domination over other regions in terms of market share by revenue. It has a higher value share and is poised to grow at a higher growth rate to reflect a CAGR of 8.4% throughout the forecast period, 2017 to 2022
2. Asia-Pacific excluding Japan (APEJ) shows the highest growth rate and poised to register a CAGR of 8.7% during the period of forecast, owing to rapid development and higher foreign direct investment in this region. Following APEJ, Europe region also reflects good rate of growth in the global peptide based infection therapeutics market
3. By drug class, telaprivir shows higher market share by revenue as compared to boceprevir. However, boceprivir shows a higher growth rate to reflect a CAGR of 8.2% during the period of forecast. It can be said that, even though telaprevir segment has a market share which is almost one and a half times than that of  boceprevir, the boseprivir segment, could match the market share at this high growth rate post 2022, a market observation which would depend on the current growth rate of boceprivir and its consistency through 2017 to 2022 and even beyond
4. The online pharmacies segment by distribution channel shows the fastest growth rate and is poised to reflect a CAGR of 9.2% throughout the period of forecast of 2017 to 2022. Yet, this segment shows less market share by revenue as compared to other segments.
5. The hospital pharmacy segment enjoys the highest market revenue share followed by retail pharmacy segment. The retail pharmacy segment, however, reflects a higher growth rate as compared to the hospital pharmacy segment. It would be only appropriate to track these two segments who have a toe to toe competition, in order to check the scenarios by the end of 2022
6. The online pharmacies segment finds North America region to be the most lucrative and has the highest growth in this region comparatively. The APEJ region is much favorable for the hospital and retail pharmacies segment followed by Europe. Latin America and Middle East and Africa region show less attractiveness comparatively

Know the methodology behind the report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=188

Telaprivir Set to Dominate the Global Market

The telaprivir segment by drug type is expected to dominate the market in terms of market share by revenue, as of 2016 and expected to show a similar trend in 2017 as well. However, the boceprevir segment grows at a higher rate during the period of forecast as compared to telaprivir yet experiences less market share by revenue comparatively. However, with the higher rate of growth throughout the forecast period, it could be a case that the domination title might shift from telaprivir to boceprivir.

Online Pharmacies to Show Robust Growth Rate, Would Just be an Understatement

The online pharmacies segment by distribution channel is anticipated to show exponential growth rate to register a CAGR of 9.2% throughout the period of forecast, 2017 to 2022. This growth can be attributed towards the increasing awareness of the online concept, its effectiveness, reliability and convenience. However, this segment, still being in its nascent phase, has less market share as compared to other segments in the distribution channel category. The online segment is also expected to experience a higher gain in the BPS by the end of 2022. The online pharmacies segment reflects the highest growth in the North America region rate as compared to other regions during the period of forecast.

Hospital vs. Retail Pharmacies, a Touch Call to Make

Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market, as per market observations in 2016 and 2017. This trend could keep up with the growth rate that it reflects. However, the retail pharmacies segment shows a higher growth rate, yet less market share. It is anticipated to reflect a higher growth rate and poised to register a CAGR of 7.9% during the period of forecast of 2017 to 2022. The regions favoring the growth of the hospital pharmacy segment is APEJ followed by Europe. APEJ is also favorable for retail pharmacies segment, in fact the growth of retail pharmacies in this region is the highest as compared to other regions, as per anticipations. Asia-Pacific excluding Japan expected to stay strong with respect to all the segments by distribution channel, except for the online pharmacies segment which finds better shelter in North America region.

Table of Content:

1. Global Peptide Based Infection Therapeutics Market – Executive Summary
2. Global Peptide Based Infection Therapeutics Market Overview
   2.1. Introduction
   2.1.1. Global Peptide Based Infection Therapeutics Market Taxonomy
   2.1.2. Global Peptide Based Infection Therapeutics Market Definition
   2.2. Global Peptide Based Infection Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
   2.2.1. Global Peptide Based Infection Therapeutics Market Y-o-Y Growth
   2.3. Global Peptide Based Infection Therapeutics Market Dynamics
   2.4. Regulations
   2.5. Supply Chain
   2.6. Cost Structure
   2.7. Average Pricing Analysis
   2.8. Epidemiology
   2.9. Key Participants Market Presence (Intensity Map) By Region
3. Global Peptide Based Infection Therapeutics Market Analysis and Forecast By Drug
   3.1. Global Peptide Based Infection Therapeutics Market Size and Forecast By Drug, 2012-2022
   3.1.1. Telaprevir Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
   3.1.1.1. Revenue (US$ Mn) Comparison, By Region
   3.1.1.2. Market Share Comparison, By Region
   3.1.1.3. Y-o-Y growth Comparison, By Region
   3.1.2. Boceprevir Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
   3.1.2.1. Revenue (US$ Mn) Comparison, By Region
   3.1.2.2. Market Share Comparison, By Region
   3.1.2.3. Y-o-Y growth Comparison, By Region
4. Global Peptide Based Infection Therapeutics Market Analysis and Forecast By Distribution Channel
   4.1. Global Peptide Based Infection Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
   4.1.1. Hospital Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
   4.1.1.1. Revenue (US$ Mn) Comparison, By Region
   4.1.1.2. Market Share Comparison, By Region
   4.1.1.3. Y-o-Y growth Comparison, By Region
   4.1.2. Retail Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
   4.1.2.1. Revenue (US$ Mn) Comparison, By Region
   4.1.2.2. Market Share Comparison, By Region
   4.1.2.3. Y-o-Y growth Comparison, By Region
   4.1.3. Online Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
   4.1.3.1. Revenue (US$ Mn) Comparison, By Region
   4.1.3.2. Market Share Comparison, By Region
   4.1.3.3. Y-o-Y growth Comparison, By Region

Continued……………..

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based infection therapeutics market through 2022, which include Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. and Parchem Fine & Specialty Chemicals.

Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=188

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/